Silicon Quantum Dot Functionalization Optimizes Anticancer Drug Thioguanine Delivery System

August 17, 2026

Frontiers in Molecular Biosciences Switzerland

Overview

Research highlights silicon quantum dots (SiQDs) as an optimal strategy for designing high-performance, reversible, and targeted silicon-based drug delivery systems. Functionalization with -COOH and -OH groups was evaluated, revealing that doubly carboxylated SiQDs significantly enhanced thioguanine adsorption, achieving the highest binding energy and shortest interaction distance. This substantially broadens nanomedicine’s potential in personalized cancer therapy.

In Depth

Key Findings

In the development of high-performance drug delivery systems, surface functionalization of silicon quantum dots (SiQDs) has emerged as a crucial breakthrough. Specifically, SiQDs functionalized with -COOH (carboxyl) and -OH (hydroxyl) groups are identified as an optimal strategy for designing reversible and targeted silicon-based drug delivery systems. This research reports that doubly carboxylated SiQDs significantly enhanced the adsorption capacity of the anticancer drug thioguanine, achieving unprecedentedly high binding energy and the shortest interaction distance. This promises efficient drug loading and specific delivery to cells, potentially contributing significantly to personalized cancer therapy.

Technical / Clinical Details

SiQDs are gaining attention as promising nanocarriers for bioimaging and drug delivery due to their low toxicity, excellent biocompatibility, and tunable optical properties. In this study, researchers aimed to precisely control drug loading characteristics and release kinetics by introducing different chemical functional groups to the SiQD surface. Functionalization with carboxyl (-COOH) and hydroxyl (-OH) groups was evaluated in detail, as these groups can enhance interactions with biomolecules and drugs, thereby modifying SiQD surface properties.

The most significant finding was that doubly carboxylated SiQDs demonstrated an extremely high adsorption capacity for the anticancer drug thioguanine. This is attributed to multiple carboxyl groups on the SiQD surface forming stable, multi-point bonds with specific sites on thioguanine. Simulations and experimental results confirmed that this complex possessed the highest binding energy and shortest interaction distance. This enables the design of a reversible system where drugs are loaded at high density onto SiQDs, preventing premature release in vivo while efficiently releasing the drug upon reaching target cells.

This technology can be further developed into an ultratargeted drug delivery system by modifying the SiQD surface with ligands (e.g., antibodies or peptides) that specifically bind to cancer cells. This approach aims to minimize systemic toxicity of anticancer drugs while concentrating them at tumor sites, expecting enhanced therapeutic efficacy and reduced side effects.

Background & Context

Cancer treatment faces challenges such as drug side effects, acquired resistance, and low drug delivery efficiency to tumors. Nanomedicine offers a promising approach to overcome these challenges, with extensive research focused on using nanoparticles as carriers for efficient and selective drug delivery. SiQDs are gaining attention as heavy metal-free alternatives that circumvent the toxicity concerns of heavy metal-based quantum dots. Their biocompatibility and ease of chemical modification make them promising foundational materials for next-generation drug delivery systems. This research provides specific design guidelines for applying SiQDs in cancer therapy, accelerating innovation in the nanomedicine field.

Strategic Significance & Outlook

This drug delivery strategy using SiQDs holds significant potential for advancing personalized cancer therapy. Future work is expected to further optimize this technology and conduct additional in vitro and in vivo evaluations to translate it into clinical applications. It will be crucial to explore its applicability to different anticancer drugs and therapeutic agents for various diseases. Improving the scalability and cost-efficiency of SiQD synthesis processes will also be key challenges for commercialization. This achievement, through the fusion of nanomaterials science and drug delivery technology, paves the way for a future where safer and more effective treatments are available to patients.

Source: https://www.frontiersin.org/journals/nanotechnology/articles/10.3389/fnano.2026.1833993/full

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.